Metallodrugs against Cancer Cells: Mechanisms of Action and Molecular Targets
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 15 May 2024 | Viewed by 92
Special Issue Editors
Interests: gastroenterology; intestine; intestinal microbiota; intestinal inflammation; TLR signaling; serotoninergic system; intestinal motility; colon cancer; metallodrugs; nanomolecules
Special Issues, Collections and Topics in MDPI journals
Interests: organometallic synthesis; cell biology; bioinorganic chemistry; cancer research; oxidative stress assays; cytotoxicity; primary cell culture; colon cancer
Special Issue Information
Dear Colleagues,
Many years of research have been conducted since the discovery of cisplatin- and platinum-based drugs as chemotherapists. Currently, research into new therapies for colon cancer based on new selective metallic compounds that act on new mechanisms of action and have fewer side effects is of great scientific interest. In these terms, there are several proteins or biomolecules specifically overexpressed in most human tumors that can be used as targets for metallodrugs. These cancer-related proteins play roles in inhibiting metastasis, angiogenesis, and proliferation. For these reasons, metallodrugs are interesting and promising in the next steps of antitumor therapy.
Metal complexes represent a huge field to explore thanks to their great versatility and different chemistry. Therefore, by changing a small moiety of the complex, the interaction with the molecular target can be changed drastically and, consequently, so can the mechanism of action and cell death. Additionally, some properties such as thermal behavior, optical properties and photostability could also improve the selectivity towards tumor cells.
This Special Issue of Cells, entitled “Metallodrugs against Cancer Cells: Mechanisms of Action and Molecular Targets”, welcomes original research articles focusing on the aspects of design and characterization of new metallodrugs that target new molecular mechanisms of cancer biology in order to improve the therapy and/or diagnosis of cancer.
Dr. Laura Grasa
Dr. Elisa Abás
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell death
- cytotoxicity
- molecular mechanism
- cell imaging
- theragnostic
- photodynamic therapy
- chemotherapy
- gene expression
- drug uptake
- SAR studies
